Wave Life Sciences, Inc. (WVE)
3.78
-0.18
(-4.55%)
USD |
NASDAQ |
Sep 25, 16:00
3.80
+0.02
(+0.53%)
After-Hours: 07:35
Wave Life Sciences Enterprise Value : 283.58M for Sept. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 25, 2026 | 283.58M |
| September 24, 2026 | 318.37M |
| September 23, 2026 | 316.43M |
| September 22, 2026 | 393.75M |
| September 21, 2026 | 375.38M |
| September 18, 2026 | 393.75M |
| September 17, 2026 | 411.14M |
| September 16, 2026 | 423.70M |
| September 15, 2026 | 415.01M |
| September 14, 2026 | 438.20M |
| September 11, 2026 | 440.13M |
| September 10, 2026 | 455.59M |
| September 09, 2026 | 482.65M |
| September 08, 2026 | 501.98M |
| September 04, 2026 | 492.32M |
| September 03, 2026 | 461.39M |
| September 02, 2026 | 496.18M |
| September 01, 2026 | 513.58M |
| August 31, 2026 | 500.05M |
| August 28, 2026 | 527.11M |
| August 27, 2026 | 550.30M |
| August 26, 2026 | 563.83M |
| August 25, 2026 | 567.70M |
| August 24, 2026 | 542.57M |
| August 21, 2026 | 575.43M |
| Date | Value |
|---|---|
| August 20, 2026 | 567.70M |
| August 19, 2026 | 599.59M |
| August 18, 2026 | 575.43M |
| August 17, 2026 | 536.77M |
| August 14, 2026 | 598.62M |
| August 13, 2026 | 558.03M |
| August 12, 2026 | 565.76M |
| August 11, 2026 | 528.07M |
| August 10, 2026 | 726.18M |
| August 07, 2026 | 731.98M |
| August 06, 2026 | 716.52M |
| August 05, 2026 | 699.12M |
| August 04, 2026 | 712.65M |
| August 03, 2026 | 662.40M |
| July 31, 2026 | 617.95M |
| July 30, 2026 | 666.27M |
| July 29, 2026 | 675.93M |
| July 28, 2026 | 691.39M |
| July 27, 2026 | 697.19M |
| July 24, 2026 | 675.93M |
| July 23, 2026 | 670.13M |
| July 22, 2026 | 662.40M |
| July 21, 2026 | 672.07M |
| July 20, 2026 | 660.47M |
| July 17, 2026 | 677.86M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Filana Therapeutics, Inc. | -46.54M |
| CorMedix, Inc. | 497.49M |
| Eloxx Pharmaceuticals, Inc. | -1.299M |
| Breakthrough Chemistry, Inc. | 0.2897M |
| BioStem Technologies, Inc. | 68.04M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -69.36M |
| Revenue (Quarterly) | 2.272M |
| Total Expenses (Quarterly) | 71.63M |
| EPS Diluted (Quarterly) | -0.34 |
| Gross Profit Margin (Quarterly) | -4.27% |
| Profit Margin (Quarterly) | -3.05K% |
| Earnings Yield | -28.74% |
| Normalized Earnings Yield | -28.74 |